My mother has breast cancer. Is Tamoxifen safe for her?

Question

Hello doctor,

My mother is 58 and was recently diagnosed with stage 2 breast cancer. Her biopsy showed ER/PR positive, HER2 negative, and she has been advised to undergo surgery followed by hormone therapy.

We are worried about the side effects of Tamoxifen, especially related to the uterus and clotting. My concerns are:

Are there safer alternatives in such cases?
Also, does chemotherapy become necessary even when the tumor markers look favorable?
Finally, would a genomic test like Oncotype DX really help in deciding about chemotherapy, or is it more useful only for certain subtypes?

We are feeling lost about choosing the right treatment pathway.

Please help.

Answer 1

Hello,

Welcome to icliniq.com.

I understand your concern.

At 58, an ER (estrogen receptor)/PR (progesterone receptor) positive and HER2 (human epidermal growth factor receptor 2) negative is usually a favorable profile, and the mainstay is surgery plus endocrine therapy.

She might probably have breast cancer stage II, hormone receptor positive, HER2 negative, which drives treatment towards endocrine therapy after local control. Other conditions may not be considered here, but subtype confirmation is key (luminal A versus luminal B).

So, the treatment involves

Tamoxifen is one option, but in postmenopausal women, we usually consider aromatase inhibitors (like Letrozole, Anastrozole, and Exemestane) as they avoid the uterine lining stimulation that Tamoxifen causes. The clot risk is also less with those compared to Tamoxifen.
Surgery (lumpectomy or mastectomy, depending on feasibility).
Endocrine therapy: In a 58-year-old, aromatase inhibitors are generally safer and more effective than Tamoxifen in the long term.
Chemotherapy is not always necessary if the tumor size is small, the nodes are negative, and the genomic score is low. If nodes are involved or the tumor is higher risk, then chemotherapy may be advised.
Genomic tests like Oncotype DX are most useful in ER+/HER2–, node-negative (sometimes one to three nodes positive) cases to guide whether chemotherapy adds real benefit. They are not used for HER2+ or triple-negative. So yes, in your mother’s subtype, it has real value.

Some investigations that can be done for your mother are:

Surgical pathology after tumor removal (size, nodes, or margins).
Bone mineral density should be assessed if an aromatase inhibitor is planned.
If considering a chemotherapy decision, a genomic assay (like Oncotype DX) can be ordered.

Regular follow-up every few months after treatment. Monitor bone health if aromatase inhibitors are used. Keep an active lifestyle, maintain a healthy weight, and avoid smoking or alcohol.

After surgery, please share the final pathology report (tumor size, grade, lymph node status). That will help decide on the need for chemotherapy and confirm whether genomic testing is required.

Also, update on her general health status and comorbidities, so we can tailor endocrine therapy choice.

I hope this helps.

Thank you.